Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 53 articles: HTML format

Single Articles

October 2026
1. YOUNG KS, Fanning SW
   Selective estrogen receptor degraders and their effect on the breast cancer immune microenvironment.
   J Clin Invest. 2026;136:e207633.
   PubMed     Abstract available
   
   
   
2. NAPOLITANO F, Unni N, Arteaga CL
   PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance.
   J Clin Invest. 2026;136:e207635.
   PubMed     Abstract available
   
   
   
3. XIAO Y, Yang F, Qi YJ, Chen L, et al
   Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2- breast cancer.
   J Clin Invest. 2026;136:e202305.
   PubMed     Abstract available
   
   
   
4. SERIAK D, Kim JY, Shapiro GI, Giordano A, et al
   Next-generation CDK inhibitors in HR+/HER2- breast cancer.
   J Clin Invest. 2026;136:e207631.
   PubMed     Abstract available
   
   
   
5. BAYLEY R, Qu X, Chakraborty A, Shamma M, et al
   Combined inhibition of DNA Polymerase Theta and ATR targets MYBL2-high triple-negative breast cancer stem cells.
   J Clin Invest. 2026 Oct 13:e202898. doi: 10.1172/JCI202898.
   PubMed     Abstract available
   
   
   
6. GUO C, Ellisen LW
   Antibody-drug conjugates in breast cancer: redefining targeted therapy.
   J Clin Invest. 2026;136:e207630.
   PubMed     Abstract available
   
   
   
7. FANUCCI KA, Bahnassy S, Roy AM, Sokolova A, et al
   Toward targeted therapeutics for lobular breast cancer.
   J Clin Invest. 2026;136:e207629.
   PubMed     Abstract available
   
   
   
8. WALMSLEY CS, Rodriguez A, Konstantinopoulos PA, Shapiro GI, et al
   Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.
   J Clin Invest. 2026;136:e207632.
   PubMed     Abstract available
   
   
   
9. LYU Y, Talwar V, Yang Y, Kang SS, et al
   HIF-1-mediated PPME1 expression promotes breast cancer progression via AKT activation and beta-catenin recruitment.
   J Clin Invest. 2026;136:e205415.
   PubMed     Abstract available
   
   
   
10. KAY J, Dixon-Douglas JR, Harris MA, van Geelen CT, et al
    Breast cancer immunogenicity as a spectrum: evolving concepts and therapeutic implications.
    J Clin Invest. 2026;136:e207634.
    PubMed     Abstract available
    
    
    August 2026
11. LI X, Chen T, Zhao W, Li J, et al
    FBXW5 blunts RIGI/MDA5-IFN signaling to drive immunoevasion and chemo-immune resistance in triple-negative breast cancer models.
    J Clin Invest. 2026 Aug 25:e201573. doi: 10.1172/JCI201573.
    PubMed     Abstract available
    
    
    
12. TU X, Zeng X, Sun Y, Ouyang Y, et al
    ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression.
    J Clin Invest. 2026;136:e192285.
    PubMed     Abstract available
    
    
    
13. RADLER PD, Felsheim BM, Fernandez-Martinez A, Pfefferle AD, et al
    Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance).
    J Clin Invest. 2026 Aug 4:e205962. doi: 10.1172/JCI205962.
    PubMed     Abstract available
    
    
    July 2026
14. AWADIA S, Ziemke EK, Curnutt NM, Kirk E, et al
    Targeting casein kinase 1alpha-mediated FADD phosphorylation restores sensitivity in select CDK4/6 inhibitor-resistant breast cancer models.
    J Clin Invest. 2026 Jul 28:e199483. doi: 10.1172/JCI199483.
    PubMed     Abstract available
    
    
    
15. RUIZ-SEPULVEDA JL, Bueno MJ, Mouron S, Jimenez-Renard V, et al
    Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models.
    J Clin Invest. 2026;136:e174092.
    PubMed     Abstract available
    
    
    
16. ARABZADEH M, Tang YH, Colin-Leitzinger C, Marzban S, et al
    Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.
    J Clin Invest. 2026;136:e204429.
    PubMed     Abstract available
    
    
    May 2026
17. LIN Q, Luo J, Duan Z, Luo J, et al
    Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis.
    J Clin Invest. 2026;136:e199285.
    PubMed     Abstract available
    
    
    March 2026
18. ZHU XZ, Zhou YF, Ying XH, Wang YY, et al
    Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance.
    J Clin Invest. 2026;136:e188989.
    PubMed     Abstract available
    
    
    February 2026
19. YU L, Rivas C, Liu F, Shen Y, et al
    Inflammation- and resolution-programmed myeloid circuits govern therapeutic resistance in epithelial and mesenchymal triple-negative breast cancer.
    J Clin Invest. 2026 Feb 17:e198815. doi: 10.1172/JCI198815.
    PubMed     Abstract available
    
    
    
20. LI H, De Santis MC, Tucci FA, Tosoni D, et al
    SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis.
    J Clin Invest. 2026;136:e192705.
    PubMed     Abstract available
    
    
    
21. KONG T, Ma CX
    Unraveling TIME: CD8+ T cell- and CXCL11-driven endocrine resistance in breast cancer.
    J Clin Invest. 2026;136:e200923.
    PubMed     Abstract available
    
    
    January 2026
22. LI H, Zhang Y, Lin J, Zeng J, et al
    Tumor-derived neutrophil extracellular trap-associated DNA impairs treatment efficacy in breast cancer via CCDC25-dependent epithelial-mesenchymal transition.
    J Clin Invest. 2026;136:e190557.
    PubMed     Abstract available
    
    
    December 2025
23. MA S, Han Y, Gu R, Chen Q, et al
    Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models.
    J Clin Invest. 2025;135:e180106.
    PubMed     Abstract available
    
    
    
24. ADACHI Y, Chen W, Zhang C, Wang T, et al
    Targeting kinesin family member 20A sensitizes stem-like triple-negative breast cancer cells to standard chemotherapy.
    J Clin Invest. 2025;135:e182394.
    PubMed     Abstract available
    
    
    
25. NAPOLITANO F, Wang Y, Sudhan DR, Gonzalez-Ericsson PI, et al
    CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer.
    J Clin Invest. 2025 Dec 9:e188458. doi: 10.1172/JCI188458.
    PubMed     Abstract available
    
    
    
26. ARJONEN A, Kaukonen R, Mattila E, Rouhi P, et al
    Corrigendum to Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.
    J Clin Invest. 2025;135:e201379.
    PubMed    
    
    
    November 2025
27. PALOMEQUE JA, Serra-Mir G, Blasco-Benito S, Brunel H, et al
    Estrogen Receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer.
    J Clin Invest. 2025 Nov 25:e193153. doi: 10.1172/JCI193153.
    PubMed     Abstract available
    
    
    October 2025
28. WANG S, Liang K, Hu Q, Li P, et al
    Expression of Concern for JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.
    J Clin Invest. 2025;135:e200302.
    PubMed    
    
    
    September 2025
29. KUMARI N, Wright SC, Witham CM, Monserrat L, et al
    USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer.
    J Clin Invest. 2025 Sep 23:e180927. doi: 10.1172/JCI180927.
    PubMed     Abstract available
    
    
    
30. SCHOLTEN D, El-Shennawy L, Jia Y, Zhang Y, et al
    Double-positive T cells form heterotypic clusters with circulating tumor cells to foster cancer metastasis.
    J Clin Invest. 2025;135:e193521.
    PubMed     Abstract available
    
    
    August 2025
31. KIM S, Son E, Park HR, Kim M, et al
    Dual targeting CDK4/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer models.
    J Clin Invest. 2025 Aug 12:e188839. doi: 10.1172/JCI188839.
    PubMed     Abstract available
    
    
    
32. DEVARAJAN R, Izzi V, Peltoketo H, Rask G, et al
    Corrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.
    J Clin Invest. 2025;135:e196478.
    PubMed    
    
    
    July 2025
33. ZHANG G, Jurinovic V, Bartels S, Christgen M, et al
    A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-responders.
    J Clin Invest. 2025 Jul 24:e177813. doi: 10.1172/JCI177813.
    PubMed     Abstract available
    
    
    
34. YANG Y, Chen C, Lyu Y, Gololobova O, et al
    HIF-1 promotes murine breast cancer brain metastasis by increasing production of integrin beta3-containing extracellular vesicles.
    J Clin Invest. 2025;135:e190470.
    PubMed     Abstract available
    
    
    
35. KALFEIST L, Ledys F, Petit S, Poirrier C, et al
    Co-targeting TGF-beta and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet.
    J Clin Invest. 2025;135:e184422.
    PubMed     Abstract available
    
    
    
36. SURESH S, Ford JM
    A triple-punch approach: methionine restriction enhances combination inhibitors in brain metastatic triple-negative breast cancer.
    J Clin Invest. 2025;135:e193171.
    PubMed     Abstract available
    
    
    
37. ZENG X, Zhao F, Tu X, Zhang Y, et al
    Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop.
    J Clin Invest. 2025;135:e188120.
    PubMed     Abstract available
    
    
    June 2025
38. BOSE M, Singh MI, Frodin M, Ejlertsen B, et al
    Precision screening facilitates clinical classification of BRCA2-PALB2 binding variants with benign and pathogenic functional effects.
    J Clin Invest. 2025;135:e181879.
    PubMed     Abstract available
    
    
    
39. THATTE J, Moises da Silva A, Borcsok J, Gudjonsson T, et al
    The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.
    J Clin Invest. 2025;135:e188165.
    PubMed     Abstract available
    
    
    May 2025
40. CHEN MK, Yamaguchi H, Gao Y, Xia W, et al
    FGFR3-induced Y158 PARP1 phosphorylation promotes PARP-inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models.
    J Clin Invest. 2025 May 29:e173757. doi: 10.1172/JCI173757.
    PubMed     Abstract available
    
    
    April 2025
41. YANG SY, Jin ML, Andriani L, Zhao Q, et al
    Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2- breast cancer.
    J Clin Invest. 2025 Apr 29:e183531. doi: 10.1172/JCI183531.
    PubMed     Abstract available
    
    
    January 2025
42. SAFAEE TALKHONCHEH M, Sjolund J, Bolivar P, Kurzejamska E, et al
    An Activin Receptor-Like Kinase 1-governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases.
    J Clin Invest. 2025 Jan 14:e183086. doi: 10.1172/JCI183086.
    PubMed     Abstract available
    
    
    November 2024
43. CAI Y, Liu CC, Zhang Y, Liu Y, et al
    MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.
    J Clin Invest. 2024 Nov 12:e183656. doi: 10.1172/JCI183656.
    PubMed     Abstract available
    
    
    
44. WU S, Zheng Y, Olopade OI
    The convergence of genomic medicine and translational omics in transforming breast cancer patient care.
    J Clin Invest. 2024;134:e187520.
    PubMed    
    
    
    October 2024
45. SINHA S, Callow BW, Farfel AP, Roy S, et al
    Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
    J Clin Invest. 2024;134:e170953.
    PubMed     Abstract available
    
    
    
46. KUMAR A, Goel H, Wisniewski C, Wang T, et al
    Neuropilin-2 expressing cells in breast cancer are S-nitrosylation hubs that mitigate radiation-induced oxidative stress.
    J Clin Invest. 2024 Oct 1:e181368. doi: 10.1172/JCI181368.
    PubMed     Abstract available
    
    
    September 2024
47. WINKLER J, Tan W, Diadhiou CM, McGinnis CS, et al
    Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes.
    J Clin Invest. 2024;134:e164227.
    PubMed     Abstract available
    
    
    
48. REEVES MQ
    Mapping the transcriptional evolution of human metastatic breast cancer.
    J Clin Invest. 2024;134:e183971.
    PubMed     Abstract available
    
    
    August 2024
49. SHEN Y, Yan J, Li L, Sun H, et al
    LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis.
    J Clin Invest. 2024;134:e177357.
    PubMed     Abstract available
    
    
    May 2024
50. MARCHESE E, Demehri S
    Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
    J Clin Invest. 2024;134:e180914.
    PubMed     Abstract available
    
    
    April 2024
51. JOHNSON N
    Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.
    J Clin Invest. 2024;134:e179325.
    PubMed     Abstract available
    
    
    March 2024
52. ZHU Y, Banerjee A, Xie P, Ivanov AA, et al
    Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
    J Clin Invest. 2024;134:e176390.
    PubMed     Abstract available
    
    
    January 2024
53. LUO M, Bao L, Xue Y, Zhu M, et al
    ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2.
    J Clin Invest. 2024;134:e171166.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum